Long Noncoding RNAs: Emerging Regulators of Platelet-derived Growth Factor Signaling

Abstract

In PH, no clinical trials targeting lncRNAs have been carried out, so factors such as RNA stability, optimal efficacy, dosing, consistency and potential off-target effects still need to be identified [5]. In line with the studies of Deng et al., several other PDGF/hypoxia-induced lncRNAs such as TYKRIL, LnRPT and H19 have been shown to be dysregulated in PH and to modulate the PDGF signalling pathway [14][15][16]. Thus, we need more in-depth knowledge related to the lncRNAs that are regulated under specific molecular pathways in PH, the common mechanisms driving their regulation, their additive or synergistic effects, and their cross-regulation, in order to improve our insight and assist us in reaching our therapeutic goals. Moreover, to assure optimal lncRNA-based therapies in PH, we need to identify and target "master lncRNAs" by assessing their spatiotemporal regulation and their convergent and divergent functions in PH by employing omic and bioinformatic approaches. Although the lncRNA therapeutics field is still in its infancy, progress is being made in terms of understating the role of the lncRNA landscape in PH and its therapeutic potential.

Quinoxaline Derivatives Anti-Cancer Activities Through Protein Kinases Inhibition: A review

“…The four non-receptor protein tyrosine kinases that make up the Janus kinase (JAK) family, JAK1, JAK2, JAK3, and TYK2, are crucial for cell survival, proliferation, and differentiation [28] . Our knowledge of the etiology of chronic myeloproliferative neoplasms (MPNs) was significantly advanced by the identification of somatic JAK2 mutations in individuals with these diseases.…”